Actively Recruiting
Evaluating the Safety, Dosage, and Effects of YKST02 Given by IV Infusion in Adults With Primary IgA Nephropathy
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-05-12
12
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and preliminary effects of an investigational drug called YKST02 in adults with primary IgA nephropathy IgAN who continue to have protein in their urine despite standard treatments. This early phase 1 trial also studies how the drug moves through the body and affects the immune system to better understand its potential role in treating this kidney condition. Participants will receive YKST02 through intravenous infusion during a treatment period where doses may be increased based on safety and other data. The study includes an initial dosing phase followed by dose escalation as tolerated. After treatment, there is a follow-up period to monitor safety and explore early signs of benefit. Throughout, dose and schedule adjustments are guided by ongoing safety and pharmacokineticpharmacodynamic results. Those joining the study will attend clinic visits for safety checks, laboratory tests, and sample collections of blood and urine. Researchers will track adverse events and changes in kidney function, protein levels in urine, and immune markers. The main outcomes include monitoring side effects and changes in kidney-related measures over approximately 25 weeks, ensuring careful observation of participants health throughout the study and follow-up phases.
CONDITIONS
Brief Title
A Study of YKST02 in Participants With Primary IgA Nephropathy
Research Team
Q
Qiubai Li, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here